Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism
Status:
Not yet recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
This is a non-randomized, open-label, single arm, self-controlled study of XP-8121
(levothyroxine sodium) to determine a target dose conversion factor from stably dosed oral
levothyroxine to XP-8121 (levothyroxine sodium) in patients with hypothyroidism and to assess
the safety and tolerability of XP-8121(levothyroxine sodium) after once weekly subcutaneous
injections. This study includes the following periods: Screening, Titration Period, and
Maintenance Period. The study will conclude with an End of Maintenance Visit or Early
Termination (ET) Visit.